全文获取类型
收费全文 | 307371篇 |
免费 | 25559篇 |
国内免费 | 11873篇 |
专业分类
耳鼻咽喉 | 2025篇 |
儿科学 | 4504篇 |
妇产科学 | 3787篇 |
基础医学 | 50537篇 |
口腔科学 | 4550篇 |
临床医学 | 21872篇 |
内科学 | 56579篇 |
皮肤病学 | 4469篇 |
神经病学 | 24819篇 |
特种医学 | 6006篇 |
外国民族医学 | 76篇 |
外科学 | 19712篇 |
综合类 | 41547篇 |
现状与发展 | 42篇 |
一般理论 | 6篇 |
预防医学 | 15659篇 |
眼科学 | 2817篇 |
药学 | 47969篇 |
64篇 | |
中国医学 | 12236篇 |
肿瘤学 | 25527篇 |
出版年
2024年 | 470篇 |
2023年 | 4619篇 |
2022年 | 6843篇 |
2021年 | 13289篇 |
2020年 | 10489篇 |
2019年 | 9681篇 |
2018年 | 9406篇 |
2017年 | 9517篇 |
2016年 | 10060篇 |
2015年 | 11669篇 |
2014年 | 18255篇 |
2013年 | 20895篇 |
2012年 | 18326篇 |
2011年 | 20804篇 |
2010年 | 17145篇 |
2009年 | 17340篇 |
2008年 | 17255篇 |
2007年 | 15999篇 |
2006年 | 14281篇 |
2005年 | 12403篇 |
2004年 | 10584篇 |
2003年 | 9409篇 |
2002年 | 7564篇 |
2001年 | 6364篇 |
2000年 | 5372篇 |
1999年 | 4771篇 |
1998年 | 4587篇 |
1997年 | 4201篇 |
1996年 | 3778篇 |
1995年 | 3292篇 |
1994年 | 2995篇 |
1993年 | 2571篇 |
1992年 | 2174篇 |
1991年 | 1974篇 |
1990年 | 1620篇 |
1989年 | 1407篇 |
1988年 | 1263篇 |
1987年 | 1088篇 |
1986年 | 1014篇 |
1985年 | 1633篇 |
1984年 | 1560篇 |
1983年 | 1106篇 |
1982年 | 1201篇 |
1981年 | 969篇 |
1980年 | 817篇 |
1979年 | 668篇 |
1978年 | 474篇 |
1977年 | 376篇 |
1976年 | 378篇 |
1975年 | 297篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
Prevalence of HER2 Expression and Its Correlation with Clinicopathological Parameters in Gastric or Gastroesophageal Junction Adenocarcinoma in North-East Indian Population 下载免费PDF全文
Partha S RoyTomar NyoduMunlima HazarikaB J SaikiaC BhuyanAmit InamdarC W NyutheB BorthakurJ D Sharma 《Asian Pacific journal of cancer prevention》2019,20(4):1139-1145
Objective: Human epidermal growth factor receptor 2 (erbb2/HER2) overexpression, has now been implicatedin advanced gastric and gastroesophageal junction cancers. The study was conducted to determine the rate of HER2positivity in patients with locally advanced or metastatic gastric and gastroesophageal adenocarcinoma in North-EastIndia and to assess the impact of various demographic and clinical parameters on HER2 positivity. Methods: A total of68 patients of age >18 years of gastric and gastroesophageal adenocarcinoma diagnosed on histopathological examinationfrom September 2016 to February 2018 at Dr B Borooah Cancer Institute, Assam were enrolled for the observational(epidemiological) study. All patients were subjected to the HER2 immunohistochemistry test using a FDA-approved,standardized test kit. HER2 expression was correlated with various demographic and clinicopathological parameters.Results: The overall rate of HER2 positivity in the population studied was 56% (n=38). The rate was non-significantlyhigher in male, older age group (>60 years) and Hindu population. Similarly, HER2 positivity rate was higher in patientswith well differentiated histology and was more common in patients with stage II and III diseases, but neither of theassociations is statistically significant. HER2 positivity rate was significantly higher in proximal and in GEJ tumours(56% versus 44%, P=0.002). Conclusion: HER2 overexpression was evident in 56% of the North-East Indian patientswith locally advanced and metastatic gastric and gastroesophageal adenocarcinoma. The overexpression correlatedsignificantly with primary tumour site. Routine testing of gastric and gastroesophageal tumours for HER2 expressionis recommended to provide a therapeutic advantage in Indian patients. 相似文献
52.
53.
54.
55.
56.
Yang Liu Yanyan Gao Hengliang Liu Qi Chen Jinrui Ji Kailong Jia 《Arquivos brasileiros de cardiologia》2021,116(2):229
BackgroundDual antiplatelet therapy (DAPT) is the cornerstone treatment of acute myocardial infarction (AMI).ObjectiveThe present study aimed to investigate the efficacy and safety of triple antiplatelet therapy (TAPT) in elderly female patients with diabetes and ST segment elevation myocardial infarction (STEMI), who had undergone percutaneous coronary intervention (PCI).MethodsWe designed a randomized, single-blind study. Control group A (97 elderly male patients with diabetes and STEMI, whose CRUSADE scores were < 30) received aspirin, ticagrelor, and tirofiban. A total of 162 elderly female patients with diabetes and STEMI were randomly divided into two groups according to CRUSADE score. Group B (69 patients with CRUSADE score > 31) received aspirin and ticagrelor. Group C (93 patients with CRUSADE score < 30) received aspirin, ticagrelor and tirofiban. P values < 0.05 were considered statistically significant.ResultsCompared to the findings in group A, post-PCI Thrombolysis in Myocardial Infarction (TIMI) grade 3 blood flow and TIMI myocardial perfusion grade 3 were significantly less prevalent in group B (p < 0.05). When compared to groups A and C, the incidence of major adverse complications was significantly higher in group B (p < 0.05).ConclusionTAPT could effectively reduce the incidence of major complications in elderly female patients with diabetes and STEMI. However, close attention should be paid to hemorrhage in patients receiving TAPT. (Arq Bras Cardiol. 2020; [online].ahead print, PP.0-0) 相似文献
57.
58.
《Actas urologicas espa?olas》2022,46(9):550-556
ObjectiveProstate cancer (PCa) is the second most common solid tumor in men and the fifth leading cause of cancer-related death. In advanced stage, palliative treatments are used instead of curative therapies. Therefore, finding predictive indicators seems crucial. Patients with castration-resistant prostate cancer (CRPC) that received Dx chemotherapy have been retrospectively reviewed. The aim of this study was to investigate whether docetaxel (Dx)-free interval could have a predictive value for PCa and influence other sequential therapies.Material and methodsThis clinical trial study was performed on 104 patients at Medeniyet University Oncology Clinic in 2018-2020. All CRPC patients had metastases, received Dx as first-line treatment and underwent androgen receptor axis targeted (ARAT) therapy after disease progression. We analyzed patients’ progression time after Dx therapy and the effects on sequential treatment.ResultsAfter Dx therapy, all patients received ARAT (abiraterone (ABI) n: 49 (47.1%) and enzalutamide (ENZ) n: 54 (51.9%)) as a second-line treatment, except for one patient who received cabazitaxel. There was a statistically significant relationship between the Dx-free interval and duration of response to ARAT (P<.001). The response time of ARAT treatment was <10.5 months in all patients whose Dx-free interval period was <9 months.ConclusionsOur findings support the theory that Dx-free interval can be a predictive factor for CRPC. CRPC disease can be classified as Dx-sensitive disease or Dx-resistance disease, based on the Dx-free interval. Decision on subsequent treatments could be made considering this information. 相似文献
59.
《Clinical neurophysiology》2020,131(7):1444-1452
ObjectiveTo investigate cognitive functions in non-demented patients with early-onset Parkinson's disease (PD), and to compare PARK2 gene mutation carriers and non-carriers by means of event-related brain potentials (ERPs).MethodsThe participants comprised patients with early-onset PD (EOPD) and healthy controls (HC). Patients with EOPD were divided into two groups as carriers of known pathogenic variants of PARK2 gene (EOPD-PC) and non-carriers of genes involved in familial PD (EOPD-NC). ERP data were collected during auditory oddball and visual continuous performance test (CPT).ResultsBoth EOPD groups (EOPD-PC and EOPD-NC) displayed reduced and delayed P3 in response to oddball target and CPT NoGo. CPT Go P3 was reduced in EOPD-NC but not in EOPD-PC. Oddball target N1 was reduced and P2 was enhanced in both EOPD-PC and EOPD-NC. In both cognitive tasks, RTs were prolonged and accuracy was lower in EOPD-PC and EOPD-NC.ConclusionsWe found several EOPD-related neurophysiologic changes, implying impairments in cognitive functions. Pairwise comparisons between EOPD-PC and EOPD-NC revealed no significant ERP marker.SignificanceIn this study, the confounding effect of normative aging was somewhat excluded compared with many previous studies. In contrast with the many oddball studies in non-demented PD, we clearly observed reduced and prolonged P3 in early-onset PD. Our NoGo P3 findings also contribute to the limited ERP research concerning response inhibition. 相似文献
60.
Osric A. Forrest Daniel M. Chopyk Yael Gernez Milton R. Brown Carol K. Conrad Richard B. Moss Vin Tangpricha Limin Peng Rabindra Tirouvanziam 《Journal of cystic fibrosis》2019,18(1):64-70